U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07368998) titled 'To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer' on Jan. 22.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.
Study Start Date: Feb. 27
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: Inavolisib
Participants will receive Inavolisib as per the...